Payment overview · 2025
General Payments
$135.37
8 reported records · 5 companies
Healthcare provider profile · identity verified
Steven C Farquhar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DERIDDER, LA · NPI 1538153002
Verified facts
What the public records show
CMS Open Payments records show Steven C Farquhar, MD received $135.37 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 36.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.93 | 36.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.80 | 22.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.30 | 15.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.01 | 15.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.33 | 10.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $135.37 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1100 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 659 | 87 |
| Gabapentin | Gabapentin | 494 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 439 | 71 |
| Metformin Hcl | Metformin Hcl | 416 | 66 |
| Lisinopril | Lisinopril | 411 | 80 |
| Trazodone Hcl | Trazodone Hcl | 402 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 67 |
| Losartan Potassium | Losartan Potassium | 379 | 61 |
| Eliquis | Apixaban | 365 | 33 |
| Potassium Chloride | Potassium Chloride | 360 | 54 |
| Furosemide | Furosemide | 336 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 305 | 68 |
| Nifedipine Er | Nifedipine | 261 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 235 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 49 |
| Omeprazole | Omeprazole | 218 | 32 |
| Simvastatin | Simvastatin | 218 | 43 |
| Sertraline Hcl | Sertraline Hcl | 197 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 38 |
| Donepezil Hcl | Donepezil Hcl | 195 | 22 |
| Tramadol Hcl | Tramadol Hcl | 189 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 30 |
| Glipizide Er | Glipizide | 172 | 27 |
| Buspirone Hcl | Buspirone Hcl | 167 | 27 |
| Meloxicam | Meloxicam | 165 | 31 |
| Allopurinol | Allopurinol | 159 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 159 | 29 |
| Memantine Hcl | Memantine Hcl | 158 | 14 |
| Carvedilol | Carvedilol | 146 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 25 |
| Mirtazapine | Mirtazapine | 140 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 36 |
| Levetiracetam | Levetiracetam | 135 | 13 |
| Glipizide | Glipizide | 117 | 21 |
| Jardiance | Empagliflozin | 111 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 107 | 28 |
| Divalproex Sodium | Divalproex Sodium | 103 | suppressed |
| Spironolactone | Spironolactone | 99 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 99 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 96 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 13 |
| Ezetimibe | Ezetimibe | 93 | 17 |
| Sucralfate | Sucralfate | 93 | 21 |
| Prednisone | Prednisone | 89 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 15 |
| Pregabalin | Pregabalin | 79 | 13 |
| Atenolol | Atenolol | 78 | 14 |
| Clonidine Hcl | Clonidine Hcl | 77 | 17 |
| Alprazolam | Alprazolam | 75 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 29 |
| Ramipril | Ramipril | 72 | 18 |
| Linzess | Linaclotide | 71 | 11 |
| Celecoxib | Celecoxib | 70 | 15 |
| Fluconazole | Fluconazole | 70 | 28 |
| Alendronate Sodium | Alendronate Sodium | 69 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 65 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 63 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 62 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 61 | suppressed |
| Primidone | Primidone | 61 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 19 |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Finasteride | Finasteride | 55 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 54 | suppressed |
| Mupirocin | Mupirocin | 53 | 28 |
| Olanzapine | Olanzapine | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Nystatin | Nystatin | 51 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 28 |
| Lactulose | Lactulose | 50 | 15 |
| Metformin Hcl Er | Metformin Hcl | 49 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 47 | suppressed |
| Famotidine | Famotidine | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | suppressed |
| Lovastatin | Lovastatin | 46 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 45 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 45 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 16 |
| Naproxen | Naproxen | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Telmisartan | Telmisartan | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 35 |
| Oxcarbazepine | Oxcarbazepine | 41 | suppressed |
| Rexulti | Brexpiprazole | 41 | suppressed |
| Sulindac | Sulindac | 40 | 15 |
| Azithromycin | Azithromycin | 39 | 34 |
| Cilostazol | Cilostazol | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Novolog | Insulin Aspart | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 13 |
| Humalog | Insulin Lispro | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 23 | 18 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 18 |
| Diazepam | Diazepam | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Darunavir | Darunavir | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Ozempic | Semaglutide | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 18 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Procrit | Epoetin Alfa | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Phenytoin | Phenytoin | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Lacosamide | Lacosamide | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Nifedipine | Nifedipine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ritonavir | Ritonavir | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $135.37 · 8 records | Novo Nordisk Inc | Auvelity, CAPLYTA, Cologuard Collection Kit, Ozempic, Rybelsus, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error